Individual patients’ characteristics and clinical outcomes
| UPN | Age | Sex | NHL type (stage) | Disease burden* | Previous treatment (response/duration) | Best response | PD | PFS | OS |
| Patients with responding disease | |||||||||
| 12 | 65 | M | LP (IA) | Low | 6 CVP (CR/36 mo) | CR | No | 177+ | 177+ |
| 13 | 72 | F | FL grade 1 (IIA) | Low | 6 CVP (PR/16 mo); 4 rituximab (CR/24 mo) | CR | No | 183+ | 183+ |
| 14 | 52 | F | FL grade 3A (IVA) | Low | 6 R-MegaCEOP (PR/10 mo); HDS (CR/6 mo) | CR | No | 177+ | 177+ |
| 18 | 62 | F | FL grade 1 (IIIA) | High | 6 R-CVP (CR/36 mo); 4 rituximab (CR/26 mo) | CR | No | 180+ | 180+ |
| 4 | 51 | M | FL grade 2 (IA) | Low | 4 rituximab (CR/24 mo); RT 30 Gy (CR/24 mo) | CR | Yes | 154 | 199+ |
| 1 | 49 | F | LP (IVA) | Low | 6 CVP (CR/48 mo); 8 rituximab (PR/72 mo) | PR | Yes | 63 | 202+ |
| 5 | 52 | M | FL grade 1 (IVA) | Low | 6 CVP (CR/24 mo); 4 rituximab (PR/15 mo) | PR | Yes | 6 | 193+ |
| 6 | 45 | M | FL grade 2 (IVA) | Low | 6 R-CEOP (CR/12 mo); 4 rituximab (PR/8 mo); HDS (CR/12 mo) | PR | Yes | 7 | 22 |
| Patients with stable disease | |||||||||
| 2 | 60 | M | LP (IVA) | Low | 6 CVP (PR/36 mo); 6 rituximab (CR/48 mo) | SD | Yes | 59 | 169 |
| 9 | 63 | M | LP (IVA) | High | 8 rituximab (PR/16 mo); 4 CVP (PR/18 mo); 4 R-CHOP (SD/32 mo) | SD | Yes | 70 | 186+ |
| 10 | 54 | M | FL grade 1 (IVA) | High | 8 R-CVP (CR/36 mo) | SD | Yes | 70 | 187+ |
| 11 | 72 | M | FL grade 2 (IVB) | High | 18 mo leukeran (CR/84 mo) | SD | Yes | 74 | 184+ |
| 16 | 55 | F | FL grade 1 (IVA) | Low | 6 CVP (CR/24 mo) | SD | Yes | 159 | 174+ |
| 17 | 65 | M | LP (IIIA) | Low | 8 CVP (CR/98 mo) | SD | Yes | 11 | 174+ |
| Patients with progressive disease | |||||||||
| 3 | 60 | M | FL grade 2 (IVA) | Low | 8 CHOP (PR/16 mo); 6 rituximab (PR/8 mo) | PD | Yes | 1 | 199+ |
| 7 | 50 | M | FL grade 1 (IVA) | High | 6 CHOP (PR/12 mo); 4 rituximab (PR/6 mo) | PD | Yes | 1 | 189+ |
| 8 | 56 | M | FL grade 2 (IA) | High | 3 CHOP-bleo/3 CVP (RC/16 mo); HDS (CR/24 mo); 8 rituximab (CR/6 mo) | PD | Yes | 1 | 73 |
| 15 | 72 | M | LP (IA) | High | 3 CHOP (PR/8 mo); splenectomy +RT (PR/12 mo); 12 mo leukeran (PR/7 mo); HDS (CR/12 mo); 4 rituximab (PD/na) | PD | Yes | 1 | 21 |
*Low disease burden was defined as the presence of nodal masses ≤3 cm and no massive bone marrow involvement, whereas high disease burden was defined as the presence of nodal masses >3 cm and/or massive bone marrow involvement.
+, specific event not experienced at the data cut-off date; CEOP, cyclophosphamide, epi-adryamicin, vincristine, and prednisone; CHOP, cyclophosphamide, adryamicin, vincristine and prednisone; CHOP-bleo, CHOP plus bleomycin; CR, complete response; CVP, cyclophosphamide, vincristine and prednisone; F, female; FL, follicular lymphoma; HDS, high-dose sequential chemotherapy; LP, lymphoplasmocytoid NHL; M, male; mo, months; NHL, non-Hodgkin lymphoma; PD, progressive disease; PR, partial response; R-Benda, rituximab and bendamustine; R-CEOP, rituximab plus CEOP; R-CVP, rituximab plus CVP; RT, radiotherapy; SD, stable disease; UPN, unique progressive number.